BSE Live
Apr 10, 16:01Prev. Close
71.39
Open Price
68.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 10, 15:42Prev. Close
71.57
Open Price
70.60
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
72.20 (291)
| Key Financial Ratios of Brooks Laboratories (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | |
| Per Share Ratios | |||||
| Basic EPS (Rs.) | 11.17 | 11.46 | 56.51 | 17.76 | |
| Diluted EPS (Rs.) | 11.17 | 11.46 | 56.51 | 17.76 | |
| Cash EPS (Rs.) | 12.29 | 13.18 | 62.77 | 22.66 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 29.12 | 32.31 | 84.27 | 27.76 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 29.12 | 32.31 | 84.27 | 27.76 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 96.90 | 173.86 | 444.59 | 368.11 | |
| PBDIT/Share (Rs.) | 16.13 | 22.26 | 85.47 | 38.70 | |
| PBIT/Share (Rs.) | 15.03 | 20.56 | 79.35 | 33.93 | |
| PBT/Share (Rs.) | 11.76 | 12.39 | 61.28 | 22.20 | |
| Net Profit/Share (Rs.) | 11.17 | 11.46 | 56.51 | 17.76 | |
| Profitability Ratios | |||||
| PBDIT Margin (%) | 16.64 | 12.80 | 19.22 | 10.51 | |
| PBIT Margin (%) | 15.50 | 11.82 | 17.84 | 9.21 | |
| PBT Margin (%) | 12.13 | 7.12 | 13.78 | 6.02 | |
| Net Profit Margin (%) | 11.52 | 6.58 | 12.71 | 4.82 | |
| Return on Networth / Equity (%) | 38.35 | 35.46 | 67.06 | 63.97 | |
| Return on Capital Employed (%) | 19.78 | 11.77 | 19.70 | 11.17 | |
| Return on Assets (%) | 13.92 | 9.23 | 13.82 | 7.51 | |
| Total Debt/Equity (X) | 0.87 | 1.92 | 2.31 | 4.58 | |
| Asset Turnover Ratio (%) | 120.83 | 140.16 | 108.77 | 155.69 | |
| Liquidity Ratios | |||||
| Current Ratio (X) | 1.62 | 2.15 | 2.14 | 1.33 | |
| Quick Ratio (X) | 1.19 | 1.65 | 1.54 | 0.93 | |
| Inventory Turnover Ratio (X) | 9.54 | 12.94 | 6.00 | 12.09 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | |||||
| Enterprise Value (Cr.) | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/EBITDA (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| MarketCap/Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/Net Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Yield | 0.00 | 0.00 | 0.00 | 0.00 |
18.02.2026
Brooks Labs Consolidated December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
10.02.2026
Brooks Labs Standalone December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
04.12.2025
Brooks Labs Consolidated September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
27.11.2025
Brooks Labs Standalone September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
18.02.2026
Brooks Labs Consolidated December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
10.02.2026
Brooks Labs Standalone December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
04.12.2025
Brooks Labs Consolidated September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
27.11.2025
Brooks Labs Standalone September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
10.04.2026
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth